NIH R01 · 2024
Anti-tumor potential of temperature-sensitive p53 mutants
The p53 tumor suppressor is frequently inactivated by mutations in cancer. Most p53 point mutations are located in the DNA binding domain that prevent folding or disrupt the DNA binding surface. Rescuing the structural defect and transcriptional activity of mutant p53 in tumor cells should induce cell death or cell cycle arrest that bring significant therapeutic benefits. However, this hypothesis remains unproven because currently there are no specific drugs capable of efficiently reactivating mutant p53. To bypass this limitation and rigorously test the clinical potential of mutant p53 functional rescue, we established a procedure to induce sustained hypothermia in mice by pharmacological…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.